Comparison of Pavlik Harness treatment regimens for reduced but dislocatable (Barlow positive) hips in infantile DDH

David Neal, Terri Beckwith, Adam Hines, Wei Chun Lee, Bekir Eray Kilinc, Chan Hee Jo, Harry K Kim

Research output: Contribution to journalArticle

Abstract

Objective: Although the Pavlik Harness (PH) is the most utilized treatment for developmental dysplasia of the hip (DDH), the ideal treatment protocol (frequency of clinic visits in the first month and daily wear duration) for Barlow ​+ ​hips (reduced but dislocatable) has yet to be defined. Methods: This study compared DDH patients with Barlow hips who were treated with 23 vs 24 h per day PH wear and weekly vs every other week visits. Clinical success was defined as a stable hip that did not require closed or open reduction, or the use of an abduction orthosis prior to achieving clinical stability. Radiographic success was based on the acetabular index at 2-year follow up. Results: Sixty-five patients (75 hips/58 females) with Barlow hips had a mean age of presentation of 15 ± 12 days (range 4–70) and mean follow-up of 33 ± 17 months (range 6–90). There was no difference in clinical or radiographic success rate between 23 h vs 24 h wear groups (p > 0.99 both) or the Frequently vs Infrequent visit groups (p = 0.49 both). Overall clinical success rate was 97% (73/75 hips) and radiographic success rate at 2 years was 97% (58/60 hips). Conclusion: A strict, weekly clinic visit and 24-h PH regimen may not be necessary to obtain good clinical and radiographic outcomes in infants presenting <6 months of age with Barlow positive hips. Level of evidence: Therapeutic, Level III.

Original languageEnglish (US)
Pages (from-to)440-444
Number of pages5
JournalJournal of Orthopaedics
Volume16
Issue number5
DOIs
StatePublished - Sep 1 2019

Fingerprint

Hip Dislocation
Hip
Therapeutics
Ambulatory Care
Orthotic Devices
Clinical Protocols

Keywords

  • Barlow positive hip
  • DDH
  • Developmental dysplasia of the hip
  • Pavlik harness

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Comparison of Pavlik Harness treatment regimens for reduced but dislocatable (Barlow positive) hips in infantile DDH. / Neal, David; Beckwith, Terri; Hines, Adam; Lee, Wei Chun; Kilinc, Bekir Eray; Jo, Chan Hee; Kim, Harry K.

In: Journal of Orthopaedics, Vol. 16, No. 5, 01.09.2019, p. 440-444.

Research output: Contribution to journalArticle

Neal, David ; Beckwith, Terri ; Hines, Adam ; Lee, Wei Chun ; Kilinc, Bekir Eray ; Jo, Chan Hee ; Kim, Harry K. / Comparison of Pavlik Harness treatment regimens for reduced but dislocatable (Barlow positive) hips in infantile DDH. In: Journal of Orthopaedics. 2019 ; Vol. 16, No. 5. pp. 440-444.
@article{09987c3f4119446ea8487989f6363a9e,
title = "Comparison of Pavlik Harness treatment regimens for reduced but dislocatable (Barlow positive) hips in infantile DDH",
abstract = "Objective: Although the Pavlik Harness (PH) is the most utilized treatment for developmental dysplasia of the hip (DDH), the ideal treatment protocol (frequency of clinic visits in the first month and daily wear duration) for Barlow ​+ ​hips (reduced but dislocatable) has yet to be defined. Methods: This study compared DDH patients with Barlow hips who were treated with 23 vs 24 h per day PH wear and weekly vs every other week visits. Clinical success was defined as a stable hip that did not require closed or open reduction, or the use of an abduction orthosis prior to achieving clinical stability. Radiographic success was based on the acetabular index at 2-year follow up. Results: Sixty-five patients (75 hips/58 females) with Barlow hips had a mean age of presentation of 15 ± 12 days (range 4–70) and mean follow-up of 33 ± 17 months (range 6–90). There was no difference in clinical or radiographic success rate between 23 h vs 24 h wear groups (p > 0.99 both) or the Frequently vs Infrequent visit groups (p = 0.49 both). Overall clinical success rate was 97{\%} (73/75 hips) and radiographic success rate at 2 years was 97{\%} (58/60 hips). Conclusion: A strict, weekly clinic visit and 24-h PH regimen may not be necessary to obtain good clinical and radiographic outcomes in infants presenting <6 months of age with Barlow positive hips. Level of evidence: Therapeutic, Level III.",
keywords = "Barlow positive hip, DDH, Developmental dysplasia of the hip, Pavlik harness",
author = "David Neal and Terri Beckwith and Adam Hines and Lee, {Wei Chun} and Kilinc, {Bekir Eray} and Jo, {Chan Hee} and Kim, {Harry K}",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jor.2019.06.027",
language = "English (US)",
volume = "16",
pages = "440--444",
journal = "Journal of Orthopaedics",
issn = "0972-978X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Comparison of Pavlik Harness treatment regimens for reduced but dislocatable (Barlow positive) hips in infantile DDH

AU - Neal, David

AU - Beckwith, Terri

AU - Hines, Adam

AU - Lee, Wei Chun

AU - Kilinc, Bekir Eray

AU - Jo, Chan Hee

AU - Kim, Harry K

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective: Although the Pavlik Harness (PH) is the most utilized treatment for developmental dysplasia of the hip (DDH), the ideal treatment protocol (frequency of clinic visits in the first month and daily wear duration) for Barlow ​+ ​hips (reduced but dislocatable) has yet to be defined. Methods: This study compared DDH patients with Barlow hips who were treated with 23 vs 24 h per day PH wear and weekly vs every other week visits. Clinical success was defined as a stable hip that did not require closed or open reduction, or the use of an abduction orthosis prior to achieving clinical stability. Radiographic success was based on the acetabular index at 2-year follow up. Results: Sixty-five patients (75 hips/58 females) with Barlow hips had a mean age of presentation of 15 ± 12 days (range 4–70) and mean follow-up of 33 ± 17 months (range 6–90). There was no difference in clinical or radiographic success rate between 23 h vs 24 h wear groups (p > 0.99 both) or the Frequently vs Infrequent visit groups (p = 0.49 both). Overall clinical success rate was 97% (73/75 hips) and radiographic success rate at 2 years was 97% (58/60 hips). Conclusion: A strict, weekly clinic visit and 24-h PH regimen may not be necessary to obtain good clinical and radiographic outcomes in infants presenting <6 months of age with Barlow positive hips. Level of evidence: Therapeutic, Level III.

AB - Objective: Although the Pavlik Harness (PH) is the most utilized treatment for developmental dysplasia of the hip (DDH), the ideal treatment protocol (frequency of clinic visits in the first month and daily wear duration) for Barlow ​+ ​hips (reduced but dislocatable) has yet to be defined. Methods: This study compared DDH patients with Barlow hips who were treated with 23 vs 24 h per day PH wear and weekly vs every other week visits. Clinical success was defined as a stable hip that did not require closed or open reduction, or the use of an abduction orthosis prior to achieving clinical stability. Radiographic success was based on the acetabular index at 2-year follow up. Results: Sixty-five patients (75 hips/58 females) with Barlow hips had a mean age of presentation of 15 ± 12 days (range 4–70) and mean follow-up of 33 ± 17 months (range 6–90). There was no difference in clinical or radiographic success rate between 23 h vs 24 h wear groups (p > 0.99 both) or the Frequently vs Infrequent visit groups (p = 0.49 both). Overall clinical success rate was 97% (73/75 hips) and radiographic success rate at 2 years was 97% (58/60 hips). Conclusion: A strict, weekly clinic visit and 24-h PH regimen may not be necessary to obtain good clinical and radiographic outcomes in infants presenting <6 months of age with Barlow positive hips. Level of evidence: Therapeutic, Level III.

KW - Barlow positive hip

KW - DDH

KW - Developmental dysplasia of the hip

KW - Pavlik harness

UR - http://www.scopus.com/inward/record.url?scp=85071628233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071628233&partnerID=8YFLogxK

U2 - 10.1016/j.jor.2019.06.027

DO - 10.1016/j.jor.2019.06.027

M3 - Article

VL - 16

SP - 440

EP - 444

JO - Journal of Orthopaedics

JF - Journal of Orthopaedics

SN - 0972-978X

IS - 5

ER -